Narrative review examines ulcerative colitis and colorectal cancer risk

Photo by Bioscience Image Library by Fayette Reynolds / Unsplash

Frontiers in Medicine Published April 17, 2026 Medically reviewed April 25, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider ulcerative colitis as a risk factor for colorectal cancer based on existing evidence.

This is a narrative review focusing on the relationship between ulcerative colitis and colorectal cancer risk. It explores various factors that may influence this association, such as disease duration, extent, and inflammation, drawing from previously published studies without conducting a systematic search or meta-analysis.

The authors synthesize qualitative conclusions from the literature, highlighting that ulcerative colitis is linked to an increased risk of colorectal cancer, though the exact magnitude and mechanisms are not detailed. They note that surveillance strategies and preventive measures are discussed based on existing evidence, but no new numerical data or pooled effect sizes are provided.

Limitations include the narrative nature of the review, which may lack comprehensive coverage or rigorous methodology compared to systematic reviews. The authors do not report specific gaps, but the absence of pooled data and reliance on prior studies suggest potential biases or incomplete synthesis.

In terms of practice relevance, the review reinforces the need for vigilance in monitoring ulcerative colitis patients for colorectal cancer, but clinicians should rely on more robust evidence like guidelines or meta-analyses for decision-making. The conclusions are derived from existing literature and should be applied with caution.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

Patients with ulcerative colitis (UC) have an increased risk of developing colorectal cancer through inflammation-driven carcinogenesis distinct from sporadic disease. Although the relative risk remains elevated, contemporary population-based studies indicate a substantial decline in absolute incidence, likely reflecting improved disease control, biologic therapies and structured surveillance colonoscopy. This review synthesizes current evidence on the epidemiology and determinants of colitis-associated colorectal cancer (CAC), highlighting key risk modifiers such as disease extent and duration, persistent inflammation, family history, and primary sclerosing cholangitis. We further summarize advances in understanding the molecular and immunologic mechanisms underlying CAC, including genomic instability, immune dysregulation, oxidative stress, microbiome alterations, and tumor microenvironment remodeling. Emerging molecular and histologic biomarkers that may enhance risk stratification and guide precision surveillance are discussed. In addition, contemporary surveillance approaches and evolving chemoprevention strategies are critically evaluated. Collectively, this review outlines current challenges and future directions for individualized CRC prevention in patients with UC.